By the end of this CME session, participants will be able to: Epidemiology and Biology Describe the epidemiology, molecular biology, and prognostic implications of HER2-positive breast cancer. Understand the role of HER2 testing (IHC, FISH) and its interpretation in guiding treatment decisions. Diagnostic and Staging Approach Apply appropriate diagnostic work-up and staging investigations for HER2+ breast cancer. Incorporate biomarker testing in treatment planning. Treatment of Early-Stage Disease Discuss neoadjuvant and adjuvant treatment strategies, including chemotherapy and HER2-targeted agents. Evaluate indications for surgery and radiation in the context of systemic therapy. Management of Advanced/Metastatic Disease Review first-line, second-line, and later-line targeted therapies for metastatic HER2+ breast cancer. Integrate novel agents and clinical trial options into care pathways. Toxicity and Supportive Care Recognize and manage cardiotoxicity and other adverse effects associated with HER2-targeted therapies. Provide patient-centered counseling to improve adherence and quality of life. Multidisciplinary and Survivorship Care Highlight the role of multidisciplinary teams (oncologists, surgeons, nurses, pharmacists, counselors). Develop survivorship care plans including surveillance, lifestyle modification, and psychosocial support.